Pharma Focus Asia

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

Monday, October 31, 2022

ALX Oncology Holdings Inc a clinicalstage immunooncology company developing therapies that block the CD checkpoint pathway today announced it has entered into a loan facility agreement with Oxford Finance LLC and Silicon Valley Bank for up to millio...

Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform

Monday, October 31, 2022

Mosaic ImmunoEngineering Inc a developmentstage biotechnology company focused on developing novel immunotherapies to treat and prevent cancer using nanotechnology today announced that two research grants totaling million from the National Cancer Ins...

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

Monday, October 31, 2022

Allogene Overland Biopharm a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics Inc Nasdaq ALLO a clinicalstage biotechnology company pioneering the development of allogeneic CAR T AlloCAR T products for cancer today announce...

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

Monday, October 31, 2022

Ardelyx Inc a biopharmaceutical company founded with a mission to discover develop and commercialize innovative firstinclass medicines that meet significant unmet medical needs today announced that its collaboration partner in Japan Kyowa Kirin Co Lt...

Preclinical Data Demonstrates SonoTran® Increased Delivery and Efficacy of ADCT-601 in Human Renal Cancer Model

Monday, October 31, 2022

OxSonics Therapeutics a clinicalstage company focused on transforming cancer treatment through SonoTran its ultrasoundbased drug delivery platform today announces positive preclinical efficacy data for SonoTran in combination with ADC Therapeutics AD...

Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration

Thursday, October 27, 2022

Purdue University and Eli Lilly and Company are establishing an innovative new pharmaceutical manufacturing scholarship program and have renewed their strategic research collaboration in a series of moves that will expand their impact in Indiana and...

FUJIFILM Diosynth Biotechnologies enters into an Agreement with Argenx to Manufacture Efgartigimod, a Monoclonal Antibody (mAb) for the Treatment of Severe Autoimmune Diseases

Thursday, October 27, 2022

FUJIFILM Diosynth Biotechnologies a world leading contract development and manufacturing organization for biologics vaccines and advanced therapies today announced an agreement with argenx to manufacture efgartigimod a monoclonal antibody mAb fragmen...

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Thursday, October 27, 2022

Castle Biosciences Inc a company improving health through innovative tests that guide patient care today announced new data from two studies demonstrating the potential of DecisionDxMelanoma and DecisionDxUM to accurately stratify risk of death from...

SK bioscience and Hilleman Laboratories to Co-develop New Vaccine Platforms

Thursday, October 27, 2022

SK bioscience a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe and Hilleman Laboratories a vaccines and biologics research and development organization committed to improving...

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy

Wednesday, October 26, 2022

Candel Therapeutics Inc a clinical stage biopharmaceutical company developing viral immunotherapies today announced a collaboration with the University of Pennsylvania Penn to study the impact of novel viral immunotherapies based on Candels proprieta...